Cochrane · systematic review · CD013474
Maintenance therapy for chronic lymphocytic leukaemia
Lee, C-H, Wu, Y-Y, Huang, T-C, et al. · Cochrane Database of Systematic Reviews · 2024 · Cochrane Library
HaematologyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
14
No studies
7
Included studies
NR
No studies 7 · 33.3%Ungraded 0 · 0%Very low 2 · 9.5%Low 7 · 33.3%Moderate 5 · 23.8%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐CD20 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia
Population: people with chronic lymphocytic leukaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Anti‐CD20 mAb maintenance therapy vs observation | HR 0.94 [0.73, 1.2] | 3 studies · 1152 participants | Moderate Downgraded: imprecision |
Health‐related quality of life Anti‐CD20 mAb maintenance therapy vs observation | no estimate extracted | 1 study · 480 participants | Low Downgraded: risk of bias, imprecision |
Grade 3/4 adverse events Anti‐CD20 mAb maintenance therapy vs observation | Rate ratio 1.34 [1.06, 1.71] | 5 studies · 1284 participants | Low Downgraded: risk of bias, inconsistency |
Progression‐free survival Anti‐CD20 mAb maintenance therapy vs observation | HR 0.61 [0.5, 0.73] | 5 studies · 1255 participants | Moderate Downgraded: risk of bias |
Treatment‐related mortality Anti‐CD20 mAb maintenance therapy vs observation | Risk ratio 0.82 [0.39, 1.71] | 4 studies · 1189 participants | Low Downgraded: imprecision, inconsistency |
Treatment discontinuation Anti‐CD20 mAb maintenance therapy vs observation | Risk ratio 0.93 [0.72, 1.2] | 6 studies · 1321 participants | Low Downgraded: imprecision, inconsistency |
All adverse events Anti‐CD20 mAb maintenance therapy vs observation | Rate ratio 1.23 [1.03, 1.47] | 6 studies · 1321 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Immunomodulatory drug maintenance therapy compared to placebo/observation for people with chronic lymphocytic leukaemia
Population: people with chronic lymphocytic leukaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival Immunomodulatory drug maintenance therapy vs placebo/observation | HR 0.91 [0.61, 1.35] | 3 studies · 461 participants | Moderate Downgraded: imprecision |
Health‐related quality of life – not reported Immunomodulatory drug maintenance therapy vs placebo/observation | no estimate extracted | NR | No studies |
Grade 3/4 adverse events Immunomodulatory drug maintenance therapy vs placebo/observation | Rate ratio 1.82 [1.38, 2.38] | 2 studies · 400 participants | Low Downgraded: imprecision |
Progression‐free survival Immunomodulatory drug maintenance therapy vs placebo/observation | HR 0.37 [0.19, 0.73] | 3 studies · 461 participants | Moderate Downgraded: inconsistency |
Treatment‐related mortality Immunomodulatory drug maintenance therapy vs placebo/observation | Risk ratio 1.22 [0.35, 4.29] | 3 studies · 458 participants | Low Downgraded: imprecision |
Treatment discontinuation Immunomodulatory drug maintenance therapy vs placebo/observation | Risk ratio 0.71 [0.47, 1.05] | 2 studies · 400 participants | Very low Downgraded: imprecision, inconsistency |
All adverse events Immunomodulatory drug maintenance therapy vs placebo/observation | Rate ratio 1.41 [1.28, 1.54] | 3 studies · 458 participants | Moderate Downgraded: imprecision, inconsistency |
Anti‐CD52 mAb maintenance therapy compared to observation for people with chronic lymphocytic leukaemia
Population: people with chronic lymphocytic leukaemia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Overall survival – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |
Health‐related quality of life – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |
Grade 3/4 adverse events – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |
Progression‐free survival Anti‐CD52 mAb maintenance therapy vs observation | HR 0.55 [0.32, 0.95] | 1 study · 21 participants | Very low Downgraded: risk of bias, imprecision |
Treatment‐related mortality – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |
Treatment discontinuation – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |
All adverse events – not reported Anti‐CD52 mAb maintenance therapy vs observation | no estimate extracted | NR | No studies |